PBR28
Multiple Sclerosis
Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Massachusetts General Hospital
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61Moderate confidence
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Multiple Sclerosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| PBR28 (this asset) | Massachusetts General Hospital | Approved | B · 63 |
| Nabiximols | Jazz Pharmaceuticals | P4 | BBB |
| Cladribine | University Hospital, Strasbourg, France | P4 | BBB |
| Ocrelizumab | Polpharma Biologics International AG | P4 | BBB |
| Teriflunomide | Sanofi | P4 | BBB |
| Fampridine | MGH Institute of Health Professions | P4 | BBB |
| Natalizumab | Biogen | P4 | BB |
| Methylphenidate | Johns Hopkins University | P3 | BB |
| Fingolimod | Biogen | P4 | BB |
+42 more in the Multiple Sclerosis cohort
Other indications for PBR28
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Alzheimer Disease | — | P2 | B · 62 |
| Lewy Body Dementia | — | P2 | B · 57 |
| Traumatic Brain Injury | — | P1/2 | CCC · 52 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. PBR28 in Multiple Sclerosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/pbr28-multiple-sclerosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →